Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy in the First-line Anti-H. Pylori Treatment
Kaohsiung Medical University
390 participants
Nov 28, 2023
INTERVENTIONAL
Conditions
Summary
1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.
Eligibility
Inclusion Criteria1
- (1) At least 18 years old. (2) Subjects infected with Helicobacter pylori.
Exclusion Criteria5
- Those who have ever received Helicobacter pylori sterilization treatment.
- Those who are allergic to the drugs used in this research.
- Those who have had stomach surgery.
- Those with severe liver cirrhosis or uremia or malignant tumors.
- Women who are pregnant or breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
bismuth-amoxicillin-vonoprazan triple therapy
vonoprazan-amoxicillin dual therapy
proton pump inhibitor-based standard triple therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06349486